The year in non-ST-segment elevation acute coronary syndromes

Journal of the American College of Cardiology

Volumn 46, Issue 5, 2005, Pages 906-919

  Giugliano, Robert P ^a,b   Braunwald, Eugene ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; GLYCOPROTEIN; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PRAVASTATIN; PURINE P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIMVASTATIN; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; HOSPITALIZATION; HUMAN; INFLAMMATION; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA;

ACUTE DISEASE; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK ASSESSMENT; RISK FACTORS; SYNDROME; TIME FACTORS;

EID: 24144473717     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.051     Document Type: Review

References (140)

1. American Heart Association Heart Disease and Stroke Statistics - 2005 Update 2005 American Heart Association Dallas, TX
2. E. Braunwald, D.B. Mark, R.H. Jones Unstable angina: diagnosis and management. Agency for Health Care Policy and Research, Clinical Practice Guideline No. 10 1994 Public Health Service, National Heart, Lung, and Blood Institute Bethesda, MD
3. E.M. Antman, M. Cohen, P.J. Bernink The TIMI risk score for unstable angina/non-ST elevation MI a method for prognostication and therapeutic decision making JAMA 284 2000 835 842
4. E. Boersma, K.S. Pieper, E.W. Steyerberg The PURSUIT Investigators Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients Circulation 101 2000 2557 2567
5. D.R. Jacobs Jr, C. Kroenke, R. Crow PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey Circulation 100 1999 599 607
6. J.E. Calvin, L.W. Klein, E.J. VandenBerg Validated risk stratification model accurately predicts low risk in patients with unstable angina J Am Coll Cardiol 36 2000 1803 1808
7. K.A. Eagle, M.J. Lim, O.H. Dabbous GRACE Investigators A validated prediction model for all forms of acute coronary syndrome JAMA 291 2004 2727 2733
8. P. de Araujo Goncalves, J. Ferreira, C. Aguiar, R. Seabra-Gomes TIMI, PURSUIT, and GRACE risk scores sustained prognostic value and interaction with revascularization in NSTEACS Eur Heart J 2005 865 872
9. M. Gulati, S. Patel, A.S. Jaffe Impact of contemporary guideline compliance on risk stratification models for acute coronary syndromes in the Registry of Acute Coronary Syndromes Am J Cardiol 94 2004 873 878
10. S. Garcia, M. Canoniero, A. Peter Correlation of TIMI risk score with angiographic severity and extent of coronary artery disease in patients with non-ST-elevation acute coronary syndromes Am J Cardiol 93 2004 813 816
11. J.L. Mega, D.A. Morrow, M.S. Sabatine Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes Am Heart J 149 2005 846 850
12. D.A. Morrow, E.M. Antman, R.P. Giugliano A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction an InTIME II substudy Lancet 358 2001 1571 1575
13. L. Ilkhanoff, C.J. O'Donnell, C.A. Camargo Jr. The TIMI risk index predicts short and long-term mortality across the spectrum of acute coronary syndromes Am J Cardiol 2005 In Press
14. D.A. Morrow, E.M. Antman, S.A. Murphy The Risk Score Profile a novel approach to characterising the risk of populations enrolled in clinical studies Eur Heart J 25 2004 1139 1145
15. M.S. Sabatine, D.A. Morrow, R.P. Giugliano Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial Circulation 109 2004 874 880
16. A.L. Blomkalns, A.Y. Chen, J.S. Hochman Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative J Am Coll Cardiol 45 2005 832 837
17. D.A. Halon, S. Adawi, I. Dobrecky-Mery Importance of increasing age on the presentation and outcome of acute coronary syndromes in elderly patients J Am Coll Cardiol 43 2004 346 352
18. M.S. Sabatine, G.J. Blake, M.H. Drazner Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment Circulation 111 2005 1217 1224
19. A.F. Sonel, C.B. Good, J. Mulgund Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?) Circulation 111 2005 1225 1232
20. M.T. Roe, W.E. Boden, A. Chen Is the "Hub and Spoke" model working? Patterns of transfer for high-risk acute coronary syndromes patients from community hospitals without revascularization capacity (abstr) J Am Coll Cardiol 43 Suppl A 2004 1A
21. P.G. Steg, O.H. Dabbous, L.J. Feldman Determinants and prognostic impact of heart failure complicating acute coronary syndromes observations from the Global Registry of Acute Coronary Events (GRACE) Circulation 109 2004 494 499
22. F.A. Masoudi, M.E. Plomondon, D.J. Magid Renal insufficiency and mortality from acute coronary syndromes Am Heart J 147 2004 623 629
23. E.M. Ohman, M.T. Roe, S.C. Smith Jr. Care of non-ST-segment elevation patients insights from the CRUSADE national quality improvement initiative Am Heart J 148 2004 S34 S39
24. D.L. Bhatt, M.T. Roe, E.D. Peterson Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes results from the CRUSADE Quality Improvement Initiative JAMA 292 2004 2096 2104
25. D.A. Morrow, E. Braunwald Future of biomarkers in acute coronary syndromes moving toward a multimarker strategy Circulation 108 2003 250 252
26. C.A. Henrikson, E.E. Howell, D.E. Bush Prognostic usefulness of marginal troponin T elevation Am J Cardiol 93 2004 275 279
27. K. Okamatsu, M. Takano, S. Sakai Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes Circulation 109 2004 465 470
28. V.R. Mandadi, M.C. DeVoe, J.A. Ambrose Predictors of troponin elevation after percutaneous coronary intervention Am J Cardiol 93 2004 747 750
29. C. Cavallini, S. Savonitto, R. Violini Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention results of the CK-MB and PCI study Eur Heart J 26 2005 1494 1498
30. L. Bolognese, K. Ducci, P. Angioli Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes Circulation 110 2004 1592 1597
31. J.B. Selvanayagam, I. Porto, K. Channon Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury insights from cardiovascular magnetic resonance imaging Circulation 111 2005 1027 1032
32. P.M. Ridker High-sensitivity C-reactive protein, inflammation, and cardiovascular risk from concept to clinical practice to clinical benefit Am Heart J 148 2004 S19 S26
33. R. Arroyo-Espliguero, P. Avanzas, J. Cosin-Sales C-reactive protein elevation and disease activity in patients with coronary artery disease Eur Heart J 25 2004 401 408
34. J.M. de la Torre-Hernandez, F. Sainz-Laso, V. Burgos Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents Am J Cardiol 95 2005 748 751
35. D.P. Vivekananthan, D.L. Bhatt, D.P. Chew Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention Am J Cardiol 94 2004 358 360
36. S. Baldus, C. Heeschen, T. Meinertz Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445
37. J.A. Vita, M.L. Brennan, N. Gokce Serum myeloperoxidase levels independently predict endothelial dysfunction in humans Circulation 110 2004 1134 1139
38. F.W. Asselbergs, J.W. Tervaert, R.A. Tio Prognostic value of myeloperoxidase in patients with chest pain (letter and reply) N Engl J Med 350 2004 516 518
39. J.A. de Lemos, D.A. Morrow, J.H. Bentley The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med 345 2001 1014 1021
40. R. Bassan, A. Potsch, A. Maisel B-type natriuretic peptide a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation Eur Heart J 26 2005 234 240
41. T.J. Wang, M.G. Larson, D. Levy Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
42. O. Bazzino, J.J. Fuselli, F. Botto Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes Eur Heart J 25 2004 859 866
43. C. Heeschen, C.W. Hamm, V. Mitrovic N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes Circulation 110 2004 3206 3212
44. G. Ndrepepa, S. Braun, J. Mehilli Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction Am J Cardiol 95 2005 553 557
45. R.J. de Winter, A. Stroobants, K.T. Koch Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention Am J Cardiol 94 2004 1481 1485
46. R. Jarai, N. Iordanova, A. Raffetseder Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide Eur Heart J 26 2005 250 256
47. M. Bartnik, L. Ryden, R. Ferrari The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart Eur Heart J 25 2004 1880 1890
48. M. Bartnik, K. Malmberg, A. Norhammar Newly detected abnormal glucose tolerance an important predictor of long-term outcome after myocardial infarction Eur Heart J 25 2004 1990 1997
49. R. Dumaine, J.P. Collet, M.L. Tanguy Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study) Am J Cardiol 94 2004 1543 1547
50. C.M. Gibson, R.L. Dumaine, E.V. Gelfand Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials Eur Heart J 25 2004 1998 2005
51. T. Jernberg, B. Lindahl, S. James Cystatin C a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome Circulation 110 2004 2342 2348
52. M. Zahid, A.F. Sonel, M.E. Kelley Effect of both elevated troponin-I and peripheral white blood cell count on prognosis in patients with suspected myocardial injury Am J Cardiol 95 2005 970 972
53. V. Bodi, J. Sanchis, A. Llacer Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes Am Heart J 149 2005 268 274
54. S.K. James, A. Siegbahn, P. Armstrong Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin a GUSTO IV substudy Am Heart J 147 2004 267 274
55. S.D. Wiviott, C.P. Cannon, D.A. Morrow Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy Circulation 109 2004 580 586
56. M. Spiecker, H. Darius, T. Hankeln Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 Circulation 110 2004 2132 2136
57. D.I. Chasman, D. Posada, L. Subrahmanyan Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2004 2821 2827
58. D.O. Williams Clopidogrel pretreatment for percutaneous coronary intervention Circulation 111 2005 2019 2021
59. T.A. Nguyen, J.G. Diodati, C. Pharand Resistance to clopidogrel a review of the evidence J Am Coll Cardiol 45 2005 1157 1164
60. C. Bal dit Sollier, I. Mahe, N. Berge Reduced thrombus cohesion in an ex vivo human model of arterial thrombosis induced by clopidogrel treatment kinetics of the effect and influence of single and double loading-dose regimens Thromb Res 111 2003 19 27
61. P.A. Gurbel, C.C. Cummings, C.R. Bell Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 145 2003 239 247
62. S.R. Steinhubl, P.B. Berger, D. Brennan CREDO Investigators Optimal timing for the initiation of pretreatment with 300 mg of clopidogrel prior to percutaneous coronary intervention J Am Coll Cardiol 2005 In press
63. W. Hochholzer, D. Trenk, D. Frundi Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
64. A. Lepantalo, K.S. Virtanen, J. Heikkila Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions Eur Heart J 25 2004 476 483
65. P.A. Gurbel, K.P. Bliden, K.M. Hayes The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 45 2005 1392 1396
66. G. Patti, G. Colonna, V. Pasceri Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Circulation 111 2005 2099 2106
67. A. Kastrati, N. von Beckerath, A. Joost Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy Circulation 110 2004 1916 1919
68. S. Silber, P. Albertsson, F.F. Aviles Guidelines for percutaneous coronary interventions the task force for percutaneous coronary interventions of the European society of cardiology Eur Heart J 26 2005 804 847
69. P.A. Gurbel, K.P. Bliden, B.L. Hiatt Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
70. S. Matetzky, B. Shenkman, V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
71. P.A. Gurbel, K.P. Bliden, W. Samara The clopidogrel resistance and stent thrombosis (CREST) study (abstr) J Am Coll Cardiol 2005 In press
72. P.A. Gurbel, K.P. Bliden, K.M. Hayes The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 45 2005 392 396
73. P. Barragan, J.L. Bouvier, P.O. Roquebert Resistance to thienopyridines clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 59 2003 295 302
74. E.I. Kapetanakis, D.A. Medlam, S.W. Boyce Clopidogrel administration prior to coronary artery bypass grafting surgery the cardiologist's panacea or the surgeon's headache? Eur Heart J 26 2005 576 583
75. K.A. Fox, S.R. Mehta, R. Peters Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 110 2004 1202 1208
76. A. Kastrati, J. Mehilli, H. Schuhlen A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med 350 2004 232 238
77. J. Mehilli, A. Kastrati, H. Schuhlen Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation 110 2004 3627 3635
78. M.J. Claeys, M.G. Van der Planken, J.M. Bosmans Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis Eur Heart J 26 2005 567 575
79. A. Schomig, C. Schmitt, A. Dibra One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel Eur Heart J 26 2005 1379 1384
80. J.M. Boeynaems, H. van Giezen, P. Savi P2Y receptor antagonists in thrombosis Curr Opin Invest Drugs 6 2005 275 282
81. L. Wallentin, T. Jernberg, P.T. Leese Inhibition of platelet aggregation with prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 receptor antagonist, compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease (abstr) J Am Coll Cardiol 45 Suppl A 2005 416A
82. S.D. Wiviott, E.M. Antman, K.J. Winters A randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, to clopidogrel in percutaneous coronary intervention; results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 111 2005 3366 3373
83. A.B. Greenbaum, E.M. Ohman, C.M. Gibson Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial Am Heart J 2005 In Press
84. G. Peters, G. Robbie Single dose pharmacokinetics and pharmacodynamics of AZD6140 - an oral reversible ADP receptor antagonist (abstr) Haematologica 89 Suppl 7 2004 14 15
85. E. Ercan, I. Tengiz, C. Duman Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction Am Heart J 147 2004 e1 e4
86. R.R. Azar, G. Badaoui, A. Sarkis Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease Am J Cardiol 95 2005 236 240
87. A. Warnholtz, M.A. Ostad, T. Heitzer Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease Am J Cardiol 95 2005 20 23
88. M. Dalby, G. Montalescot, C. Bal dit Sollier Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study J Am Coll Cardiol 43 2004 162 168
89. P.A. Gurbel, K.P. Bliden, K.A. Zaman Clopidogrel loading with eptifibatide to arrest the reactivity of platelets results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study Circulation 111 2005 1153 1159
90. A.W. Bonz, B. Lengenfelder, J. Strotmann Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial) J Am Coll Cardiol 40 2002 662 668
91. A.W. Chan, D.J. Moliterno, P.B. Berger Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) J Am Coll Cardiol 42 2003 1188 1195
92. J.-P. Dery, M.E. Campbell, C. O'Shea Administration of a loading dose amplifies the beneficial effect of thienopyridine pretreatment and complements the use of GP IIb/IIIa inhibitor therapy in patients undergoing percutaneous coronary intervention with stenting Circulation 108 Suppl 2003 IV374
93. C.M. Gibson, K.P. Singh, S.A. Murphy Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy) Am J Cardiol 94 2004 492 494
94. A.G. Rebeiz, J.P. Dery, A.A. Tsiatis Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy) Am J Cardiol 94 2004 926 929
95. A.A. Bavry, D.J. Kumbhani, R. Quiroz Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes a meta-analysis and review of the literature Am J Cardiol 93 2004 830 835
96. T. Lenderink, E. Boersma, W. Ruzyllo Bleeding events with abciximab in acute coronary syndromes without early revascularization an analysis of GUSTO IV-ACS Am Heart J 147 2004 865 873
97. J.E. Exaire, H.L. Dauerman, E.J. Topol Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices Am Heart J 147 2004 31 34
98. E. Braunwald, E.M. Antman, J.W. Beasley ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) 2002 Available at: http://www.acc.org/ clinical/guidelines/unstable/unstable/pdf. Accessed July 6, 2005
99. S.J. Denardo, K.E. Davis, J.E. Tcheng Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy Am Heart J 149 2005 138 144
100. M.A. Blazing, J.A. de Lemos, H.D. White Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin a randomized controlled trial JAMA 292 2004 55 64
101. J.J. Ferguson, R.M. Califf, E.M. Antman Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
102. J.L. Petersen, K.W. Mahaffey, V. Hasselblad Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes a systematic overview JAMA 292 2004 89 96
103. G. Montalescot, J.P. Collet, M.L. Tanguy Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin Circulation 110 2004 392 398
104. J.P. Collet, G. Montalescot, J.L. Golmard Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes Am Heart J 147 2004 655 661
105. J.A. de Lemos, M.A. Blazing, S.D. Wiviott Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy results from the A phase of the A-to-Z trial Eur Heart J 25 2004 1688 1694
106. A.M. Lincoff, N.S. Kleiman, D.J. Kereiakes Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization REPLACE-2 randomized trial JAMA 292 2004 696 703
107. J. Saw, A.M. Lincoff, W. DeSmet Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade a REPLACE-2 substudy J Am Coll Cardiol 44 2004 1194 1199
108. H.S. Gurm, V. Rajagopal, R. Fathi Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center Am J Cardiol 95 2005 716 721
109. C.M. Gibson Late-breaking clinical trials: PROTECT-TIMI 30. Advancing the Standard of Care 2004 Texas Heart Institute New Orleans, LA
110. G.W. Stone, M. Bertrand, A. Colombo Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial study design and rationale Am Heart J 148 2004 764 775
111. S.R. Mehta, P.G. Steg, C.B. Granger Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial Circulation 111 2005 1390 1397
112. D.A. Morrow, S.A. Murphy, C.H. McCabe Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36) results of the PROXIMATE-TIMI 27 trial Eur Heart J 26 2005 682 688
113. A.H. Moons, R.J. Peters, N.R. Bijsterveld Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty J Am Coll Cardiol 41 2003 2147 2153
114. C.P. Rusconi, J.D. Roberts, G.A. Pitoc Antidote-mediated control of an anticoagulant aptamer in vivo Nat Biotechnol 22 2004 1423 1428
115. W.W. O'Neill, S.R. Dixon, C.L. Grines The year in interventional cardiology J Am Coll Cardiol 45 2005 1117 1134
116. S.R. Mehta, C.P. Cannon, K.A.A. Fox Routine versus selective invasive strategies in patients with acute coronary syndromes a collaborative meta-analysis of the randomized trials JAMA 293 2005 2908 2917
117. G.G.L. Biondi-Zoccai, A. Abbate, P. Agostoni Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment a metaregression Am Heart J 149 2005 504 511
118. F.J. Neumann, A. Kastrati, G. Pogatsa-Murray Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes a randomized controlled trial JAMA 290 2003 1593 1599
119. M.J. Eisenberg, F.F. Teng, M.R. Chaudhry Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction a randomized clinical trial Am Heart J 149 2005 813 819
120. R.G. Bach, C.P. Cannon, W.S. Weintraub The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes Ann Intern Med 141 2004 186 195
121. T.C. Clayton, S.J. Pocock, R.A. Henderson Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial Eur Heart J 25 2004 1641 1650
122. S. Schellekens, F.W. Verheugt Hotline sessions of the 26th European Congress of Cardiology Eur Heart J 25 2004 2164 2166
123. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
124. K.K. Ray, C.P. Cannon, R. Cairns The timing of benefits of intensive statin therapy in ACS a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 2005 In Press
125. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
126. J.A. de Lemos, M.A. Blazing, S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z trial JAMA 292 2004 1307 1316
127. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial JAMA 291 2004 1071 1080
128. S. Okazaki, T. Yokoyama, K. Miyauchi Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study Circulation 110 2004 1061 1068
129. J.A. Lima, M.Y. Desai, H. Steen Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy Circulation 110 2004 2336 2341
130. P.M. Ridker, C.P. Cannon, D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
131. P.M. Ridker, D.A. Morrow, L.M. Rose Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol 45 2005 1644 1648
132. S.M. Macin, E.R. Perna, E.F. Farias Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome results of a randomized, double-blind, placebo-controlled study Am Heart J 149 2005 451 457
133. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
134. E.J. Whitney, R.A. Krasuski, B.E. Personius A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
135. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
136. H.B. Brewer Jr Increasing HDL cholesterol levels N Engl J Med 350 2004 1491 1494
137. C.P. Cannon, E. Braunwald, C.H. McCabe Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome N Engl J Med 352 2005 1646 1654
138. D. Mukherjee, J. Fang, S. Chetcuti Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes Circulation 109 2004 745 749
139. E. Schwammenthal, A. Sandach, R. Klempfner Predicting mortality in survivors of acute coronary syndrome using the 4 drug (4 D) score risk stratification by discharge medication (abstr) Circulation 110 Suppl III 2004 III500
140. T.J. Gluckman, M. Sachdev, S.P. Schulman A simplified approach to the management of non-ST-segment elevation acute coronary syndromes JAMA 293 2005 349 357